189 related articles for article (PubMed ID: 33443030)
1. Facilitated cascade testing (FaCT): a randomized controlled trial.
Nitecki R; Moss HA; Watson CH; Urbauer DL; Melamed A; Lu KH; Lipkin SM; Offit K; Rauh-Hain JA; Frey MK
Int J Gynecol Cancer; 2021 May; 31(5):779-783. PubMed ID: 33443030
[TBL] [Abstract][Full Text] [Related]
2. Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting.
Lee DS; Meiser B; Mariapun S; Hassan T; Yip CH; Mohd Taib NA; Teo SH; Thong MK; Yoon SY
J Genet Couns; 2021 Jun; 30(3):720-729. PubMed ID: 33245177
[TBL] [Abstract][Full Text] [Related]
3. Cascade testing in Italian Hereditary Breast Ovarian Cancer families: a missed opportunity for cancer prevention?
Trevisan L; Godino L; Battistuzzi L; Innella G; Luppi E; Buzzatti G; Gismondi V; Blondeaux E; Bonelli LA; Turchetti D; Varesco L
Fam Cancer; 2024 Jun; 23(2):197-207. PubMed ID: 37968543
[TBL] [Abstract][Full Text] [Related]
4. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
5. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
6. Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain.
Sanz J; Ramón y Cajal T; Torres A; Darder E; Gadea N; Velasco A; Fortuny D; López C; Fisas D; Brunet J; Alonso MC; Balmaña J
Fam Cancer; 2010 Sep; 9(3):297-304. PubMed ID: 20091130
[TBL] [Abstract][Full Text] [Related]
7. Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial.
Montgomery SV; Barsevick AM; Egleston BL; Bingler R; Ruth K; Miller SM; Malick J; Cescon TP; Daly MB
Fam Cancer; 2013 Sep; 12(3):537-46. PubMed ID: 23420550
[TBL] [Abstract][Full Text] [Related]
8. Direct letters to relatives at risk of hereditary cancer-study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study).
Hawranek C; Ehrencrona H; Öfverholm A; Hellquist BN; Rosén A
Trials; 2023 Dec; 24(1):810. PubMed ID: 38105176
[TBL] [Abstract][Full Text] [Related]
9. Familial communication and cascade testing among relatives of BRCA population screening participants.
Lieberman S; Lahad A; Tomer A; Koka S; BenUziyahu M; Raz A; Levy-Lahad E
Genet Med; 2018 Nov; 20(11):1446-1454. PubMed ID: 29595811
[TBL] [Abstract][Full Text] [Related]
10. A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives.
Vos J; Menko F; Jansen AM; van Asperen CJ; Stiggelbout AM; Tibben A
Fam Cancer; 2011 Mar; 10(1):87-96. PubMed ID: 20852944
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
12. From Probands to Relatives: Communication of Genetic Risk for Hereditary Breast-Ovarian Cancer and Its Influence on Subsequent Testing.
Seven M; Shah LL; Yazici H; Daack-Hirsch S
Cancer Nurs; 2022 Jan-Feb 01; 45(1):E91-E98. PubMed ID: 32804756
[TBL] [Abstract][Full Text] [Related]
13. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
14. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
15. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
16. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
17. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
[TBL] [Abstract][Full Text] [Related]
18. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
[TBL] [Abstract][Full Text] [Related]
19. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
de Juan Jiménez I; García Casado Z; Palanca Suela S; Esteban Cardeñosa E; López Guerrero JA; Segura Huerta Á; Chirivella González I; Sánchez Heras AB; Juan Fita MJ; Tena García I; Guillen Ponce C; Martínez de Dueñas E; Romero Noguera I; Salas Trejo D; Goicoechea Sáez M; Bolufer Gilabert P
Fam Cancer; 2013 Dec; 12(4):767-77. PubMed ID: 23479189
[TBL] [Abstract][Full Text] [Related]
20. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
